- Risk of infection may increase; use cautiously in patients with a chronic infection or a history of recurrent infection. Advise patient to seek medical help if signs or symptoms suggestive of an infection occur. Consider discontinuation of therapy until the infection resolves
- Evaluate patients for tuberculosis (TB) infection before initiating therapy. Treatment for latent or active TB should be initiated before starting secukinumab therapy
- Use secukinumab cautiously in patients with Crohn’s disease
- Anaphylaxis and urticaria have been reported with secukinumab therapy. If this occurs, immediately discontinue secukinumab and initiate appropriate therapy
- The removable cap of Sensoready pen and the prefilled syringe contains natural rubber latex which may cause an allergic reaction in latex-sensitive individuals
- Age appropriate immunizations should be completed before initiating secukinumab. Avoid live vaccine administration during therapy; non-live vaccinations received during therapy may not elicit an immune response sufficient to prevent disease
Cautions: Use cautiously in
- Hx of latex allergy
- Hx of chronic or recurrent infection
- Latent or active TB infection
- Crohn's disease
Pregnancy Category:B
Breastfeeding: Safety unknown. Manufacturer advises caution
